Blog

Juan P. Alderuccio: BTK inhibitors and degraders in Lymphoma and Chronic Lymphocytic Leukemia

Juan P. Alderuccio/X

Nov 4, 2024, 13:37

Juan P. Alderuccio: BTK inhibitors and degraders in Lymphoma and Chronic Lymphocytic Leukemia

Juan P. Alderuccio, Lymphoma Physician at Sylvester Comprehensive Cancer Center, shared on X about recent paper by him as co-author, titled “Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia” published on Nature Reviews Clinical Oncology.

Authors: Michele D. Stanchina, Skye Montoya, Alexey V. Danilov, Jorge J. Castillo, Alvaro J. Alencar, Julio C. Chavez, Chan Y. Cheah, Carlos Chiattone, Yucai Wang, Meghan Thompson, Paolo Ghia, Justin Taylor, Juan Pablo Alderuccio

“Happy to share our paper on BTK inhibitors and degraders in lymsm and CLL with the participation of outstanding colleagues.”

Alexey V. Danilov Alvaro J. Alencar cancer Carlos Chiattone Chan Y. Cheah Jorge J. Castillo Juan P. Alderuccio Julio C. Chavez Justin Taylor Meghan Thompson Michele D. Stanchina Nature Reviews OncoDaily Oncology Paolo Ghia Skye Montoya Yucai Wang

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage